Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is a promising company with a new ARTEMIS T-cell therapy technology platform that has the potential to unlock new opportunities in the immunology market and effectively treat solid tumors. The company's current focus on developing EB103 for B cell NHL has already shown encouraging results in Phase I trials and the ongoing Phase II trial is expected to provide additional data on treatment efficacy, safety, and market positioning. With a strong pipeline and potential milestone and royalty revenue in the future, Estrella Immunopharma has a positive outlook for financial success.

Bears say

Estrella Immunopharma is facing challenges in generating revenue from milestone and royalty payments despite having a promising pipeline for CD19 and CD22-targeted ARTEMIS T-cell therapies. The recent capital raise has extended their operational runway, but the stock's decline and potential updates on partnering and pipeline prioritization indicate concerns about future dilution. The company has made progress in its clinical and financial positions, but their revenue potential may not align with the current stock valuation.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.